ProQR Therapeutics N.V. Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
ProQR Therapeutics N.V. (PRQR) reported Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of EUR 4.01 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-03-12
- ProQR Therapeutics N.V. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2021-09-30 was 1.72M EUR, a 2.45% increase year-over-year.
- ProQR Therapeutics N.V. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2020-12-31 was 1.62M EUR.
- ProQR Therapeutics N.V. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2020-09-30 was 1.68M EUR, a 36.62% increase year-over-year.
- ProQR Therapeutics N.V. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2020-06-30 was 1.67M EUR, a 52.09% increase year-over-year.
| Period end | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 3 month | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 6 month | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 9 month | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.01M EUR 20-F · filed 2026-03-12 | |||
| 2024-12-31 | 2.54M EUR 20-F · filed 2026-03-12 | |||
| 2021-09-30 | 1.72M EUR derived: 6-K 9 month − 6-K 6 month · filed 2021-11-04 | 4.43M EUR 6-K · filed 2021-11-04 | ||
| 2021-06-30 | 2.72M EUR 6-K · filed 2021-08-05 | |||
| 2020-12-31 | 1.62M EUR derived: 6-K 12 month − 6-K 9 month · filed 2021-02-25 | 3.29M EUR derived: sum of 2 quarters · filed 2021-02-25 | 4.97M EUR derived: sum of 3 quarters · filed 2021-02-25 | 7.84M EUR 6-K · filed 2021-02-25 |
| 2020-09-30 | 1.68M EUR 6-K · filed 2020-11-16 | 3.35M EUR derived: sum of 2 quarters · filed 2020-11-16 | 6.22M EUR 6-K · filed 2021-11-04 | |
| 2020-06-30 | 1.67M EUR 6-K · filed 2020-08-06 | 1.67M EUR 6-K · filed 2021-08-05 | ||
| 2020-03-31 | 2.87M EUR 6-K · filed 2020-05-07 | |||
| 2019-12-31 | 5.95M EUR 6-K · filed 2021-02-25 | |||
| 2019-09-30 | 1.23M EUR 6-K · filed 2020-11-16 | 2.33M EUR derived: sum of 2 quarters · filed 2020-11-16 | 4.61M EUR derived: sum of 3 quarters · filed 2020-11-16 | |
| 2019-06-30 | 1.10M EUR 6-K · filed 2020-08-06 | 3.39M EUR derived: sum of 2 quarters · filed 2020-08-06 | ||
| 2019-03-31 | 2.29M EUR 6-K · filed 2020-05-07 | |||
| 2018-09-30 | 735.00K EUR 6-K · filed 2019-11-12 | 2.25M EUR derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-06-30 | 1.51M EUR 6-K · filed 2019-08-07 | 1.51M EUR 6-K · filed 2018-08-08 | ||
| 2017-06-30 | 1.27M EUR 6-K · filed 2018-08-08 |